The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).
 
Richard S. Finn
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Genentech/Roche; Lilly; Merck; Novartis; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Expert Testimony - Novartis
 
Baek-Yeol Ryoo
No Relationships to Disclose
 
Philippe Merle
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Ipsen; MSD; Onxeo; Roche
 
Masatoshi Kudo
Honoraria - Abbvie; Astellas Pharma; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Gilead Sciences; MSD; Otsuka; Taiho Pharmaceutical
Consulting or Advisory Role - Bayer; Eisai; MSD
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Mohamed Bouattour
Honoraria - Bayer; Schering Pharma
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Sirtex Medical
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Ho-Yeong Lim
No Relationships to Disclose
 
Valeriy Vladimirovich Breder
Honoraria - Bayer; BioCad; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; MSD Oncology; Roche; Takeda
Consulting or Advisory Role - Bayer; BioCad; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; MSD Oncology; Roche
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Roche; Takeda
 
Julien Edeline
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Bayer; Bristol-Myers Squibb; BTG; Ipsen
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb
 
Yee Chao
No Relationships to Disclose
 
Sadahisa Ogasawara
Honoraria - Bayer; Eisai
Consulting or Advisory Role - Bayer; Eisai
 
Thomas Yau
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb
 
Marcelo Garrido
Research Funding - Novartis; Pfizer
 
Stephen Lam Chan
Honoraria - Bayer
Consulting or Advisory Role - AstraZeneca/MedImmune; MSD Oncology; Novartis
Speakers' Bureau - Amgen; Bayer; Eisai
Research Funding - Novartis; Sirtex Medical
 
Jennifer J. Knox
Honoraria - Novartis
Consulting or Advisory Role - Lilly; Merck
Research Funding - AstraZeneca; Merck
 
Bruno Daniele
Honoraria - Bayer; Eisai; Ipsen; Lilly
Consulting or Advisory Role - Eisai; Incyte; Ipsen; MSD
Speakers' Bureau - Bristol-Myers Squibb; Eisai
Travel, Accommodations, Expenses - Bayer; Celgene
 
Scot Ebbinghaus
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Erluo Chen
Employment - Merck
 
Abby B. Siegel
Employment - Merck
 
Andrew X. Zhu
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Lilly; Merck; Novartis; Roche/Genentech
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)
 
Ann-Lii Cheng
Honoraria - AstraZeneca; Bayer Yakuhin; Eisai; Genentech/Roche; Lilly
Consulting or Advisory Role - AstraZeneca; Bayer Schering Pharma; BeiGene; Bristol-Myers Squibb; CSR Pharma; Eisai; Genentech/Roche; MSD; Novartis; Ono Pharmaceutical